Atrial fibrillation (AF) is a major worldwide public health problem, and AF in association with
valvular heart disease (VHD) is also common. However, management strategies for this …

Vitamin K antagonists (VKAs) have been the mainstay of anticoagulation therapy for more
than 50 years. VKAs are mainly used for the prevention of stroke in patients with atrial …

Purpose To examine the evidence on the cost-effectiveness of implementing
pharmacogenomics (PGx) in cardiovascular disease (CVD) care. Methods We conducted a …

Background and Purpose—The objective of the study is to compare the cost-effectiveness of
oral anticoagulants among atrial fibrillation patients at an increased stroke risk. Methods—A …

Thrombosis is a leading cause of morbidity and mortality in the United States. Arterial and
venous thromboses are implicated in the pathogenesis of major disorders, including …

Abstract Background The World Heart Federation has undertaken an initiative to develop a
series of Roadmaps to promote development of national policies and health systems …

Management strategies for patients with atrial fibrillation (AF) in association with valvular
heart disease (VHD) have been less informed by randomized trials, which have largely …

Objectives To assess cost-effectiveness of direct oral anticoagulants (DOACs) compared
with vitamin K antagonists (VKAs) for stroke prevention in atrial fibrillation (AF) by pooling …

Aims A Markov model was adapted to assess the real-world cost-effectiveness of
rivaroxaban, dabigatran and apixaban. Each of these non-vitamin K antagonist oral …

Background Atrial fibrillation (AF) remains the most common form of cardiac arrhythmia.
Management of AF aims to reduce the risk of stroke, heart failure and premature mortality via …